WO2001079274A3 - Tuberculosis antigens and methods of use thereof - Google Patents

Tuberculosis antigens and methods of use thereof Download PDF

Info

Publication number
WO2001079274A3
WO2001079274A3 PCT/DK2001/000276 DK0100276W WO0179274A3 WO 2001079274 A3 WO2001079274 A3 WO 2001079274A3 DK 0100276 W DK0100276 W DK 0100276W WO 0179274 A3 WO0179274 A3 WO 0179274A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tuberculosis antigens
polypeptides
tuberculosis
vaccines
Prior art date
Application number
PCT/DK2001/000276
Other languages
French (fr)
Other versions
WO2001079274A8 (en
WO2001079274B1 (en
WO2001079274A2 (en
Inventor
Else Marie Agger
Peter Andersen
Li Mei Meng Okkels
Karin Weldingh
Original Assignee
Statens Seruminstitut
Else Marie Agger
Peter Andersen
Li Mei Meng Okkels
Karin Weldingh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut, Else Marie Agger, Peter Andersen, Li Mei Meng Okkels, Karin Weldingh filed Critical Statens Seruminstitut
Priority to AU2001250294A priority Critical patent/AU2001250294A1/en
Priority to EP01923542A priority patent/EP1278769A2/en
Priority to CA002405247A priority patent/CA2405247A1/en
Publication of WO2001079274A2 publication Critical patent/WO2001079274A2/en
Publication of WO2001079274A3 publication Critical patent/WO2001079274A3/en
Publication of WO2001079274B1 publication Critical patent/WO2001079274B1/en
Publication of WO2001079274A8 publication Critical patent/WO2001079274A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.
PCT/DK2001/000276 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof WO2001079274A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001250294A AU2001250294A1 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof
EP01923542A EP1278769A2 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof
CA002405247A CA2405247A1 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000666 2000-04-19
DKPA200000666 2000-04-19
DKPA200100283 2001-02-21
DKPA200100283 2001-02-21

Publications (4)

Publication Number Publication Date
WO2001079274A2 WO2001079274A2 (en) 2001-10-25
WO2001079274A3 true WO2001079274A3 (en) 2002-07-11
WO2001079274B1 WO2001079274B1 (en) 2002-08-08
WO2001079274A8 WO2001079274A8 (en) 2004-04-29

Family

ID=26068815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000276 WO2001079274A2 (en) 2000-04-19 2001-04-19 Tuberculosis antigens and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1278769A2 (en)
AU (1) AU2001250294A1 (en)
CA (1) CA2405247A1 (en)
WO (1) WO2001079274A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1214088T3 (en) 1999-05-04 2009-08-24 Univ New Jersey Med Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
DE10251747A1 (en) * 2002-11-05 2004-05-19 Tuhh-Technologie-Gmbh Genetically modified penicillin amidase and process for its production
WO2004099771A1 (en) * 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
ITRM20040091A1 (en) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie QUICK IMMUNOLOGICAL TEST FOR DIAGNOSIS AND MONITORING OF TUBERCULAR INFECTION.
GB0406271D0 (en) * 2004-03-19 2004-04-21 Isis Innovation Diagnostic test
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
JP5219808B2 (en) 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート Improved tuberculosis vaccine
EP2889041A1 (en) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit of reagents for tuberculosis assay
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2741730T3 (en) 2008-05-19 2020-02-12 Advaxis Inc Double administration system for heterologous antigens comprising a recombinant Listeria strain attenuated by the dal / dat mutation and the ActA deletion comprising a nucleic acid molecule encoding a listeriolysin fusion protein O - prostate specific antigen
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
US9074001B2 (en) 2009-04-24 2015-07-07 Statens Serum Institut Tuberculosis TB vaccine to prevent reactivation
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health&Science University Methods for producing an immune response to tuberculosis
CN103282048B (en) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
ES2950436T3 (en) 2016-12-14 2023-10-10 Becton Dickinson Co Methods and compositions to obtain an assessment of tuberculosis in a subject
CN111551741B (en) * 2016-12-30 2023-06-16 首都医科大学附属北京胸科医院 Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis
GB2621127A (en) * 2022-07-29 2024-02-07 Univ Johannesburg Witwatersrand Vaccine constructs comprising tuberculosis antigens

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
WO1998053075A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999024577A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO2000066157A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
WO2000066143A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
WO1998053075A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999024577A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
WO2000066157A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
WO2000066143A1 (en) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S T COLE ET AL: "Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence", NATURE, vol. 393, 11 June 1998 (1998-06-11), pages 537 - 544, XP002901893 *

Also Published As

Publication number Publication date
WO2001079274A8 (en) 2004-04-29
CA2405247A1 (en) 2001-10-25
WO2001079274B1 (en) 2002-08-08
EP1278769A2 (en) 2003-01-29
WO2001079274A2 (en) 2001-10-25
AU2001250294A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO2001079274A8 (en) Tuberculosis antigens and methods of use thereof
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
WO2002094851A3 (en) Peptide vaccines against group a streptococci
WO1995029193A3 (en) Melanoma antigens
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO2001075087A8 (en) Subtilisin variants
CA2190473A1 (en) Recombinant papilloma virus l1
EP1449922A3 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2002083890A3 (en) Use of clya hemolysin for excretion of fusion proteins
WO2000006736A3 (en) Nucleic acids and proteins from group b streptococcus
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE3380629D1 (en) Region-specific determinants for vitamin k dependent bone protein
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
HUP0102306A3 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
EP1401493B8 (en) Subunit vaccines and processes for the production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405247

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001923542

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001250294

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001923542

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 43/2001 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001923542

Country of ref document: EP